Table 7. Response to imatinib therapy by... | American Society of Hematology

Table 7.

Response to imatinib therapy by the characteristics of the cytogenetic clonal evolution (N = 121)

Characteristic	n^7-150	Cytogenetic response, n (%)		P^7-151
Characteristic	n^7-150	Complete	Major	P^7-151
Chromosomal abnormality
Double Ph ± trisomy 8 ± other	23	8 (35)	9 (39)
Isochromosome 17 ± trisomy 8 ± other	12	2 (17)	4 (33)
Trisomy 8 ± other	13	11 (85)	11 (85)
Other translocations ± other	34	10 (29)	13 (38)	.004
Other	39	15 (38)	20 (51)
Presence of other accelerated-phase features
No	68	31 (46)	38 (56)	.05
Yes	50	13 (26)	17 (34)
Time to clonal evolution
Shorter than 12 mo	37	18 (49)	22 (59)	.09
12-23 mo	24	6 (25)	8 (33)
24 mo or longer	51	15 (29)	20 (39)
Abnormal metaphases
Less than 16%	21	10 (48)	14 (67)	.4
16%-49%	22	9 (41)	11 (50)
50% or greater	75	25 (33)	30 (40)

Characteristic	n^7-150	Cytogenetic response, n (%)		P^7-151
Characteristic	n^7-150	Complete	Major	P^7-151
Chromosomal abnormality
Double Ph ± trisomy 8 ± other	23	8 (35)	9 (39)
Isochromosome 17 ± trisomy 8 ± other	12	2 (17)	4 (33)
Trisomy 8 ± other	13	11 (85)	11 (85)
Other translocations ± other	34	10 (29)	13 (38)	.004
Other	39	15 (38)	20 (51)
Presence of other accelerated-phase features
No	68	31 (46)	38 (56)	.05
Yes	50	13 (26)	17 (34)
Time to clonal evolution
Shorter than 12 mo	37	18 (49)	22 (59)	.09
12-23 mo	24	6 (25)	8 (33)
24 mo or longer	51	15 (29)	20 (39)
Abnormal metaphases
Less than 16%	21	10 (48)	14 (67)	.4
16%-49%	22	9 (41)	11 (50)
50% or greater	75	25 (33)	30 (40)

In some patients, the characteristics could not be determined, resulting in a smaller number of patients than in the denominator.

Value for complete cytogenetic response rates.